L E T T E R T O T H E E D I T O R
Considering the results of the study published by Poluzzi et al. 1 , that also included the results on the consumption of antihistamines in 13 European countries including Serbia for the period 2005-2009/2010, it was observed that during this period the consumption of antihistamines was high in almost all the countries. Based on the Food nad Drug Administration database on spontaneous reports on adverse drug reactions, the study demonstrated a number of signals of arrhythmogenicity among the antihistamines. Five of them (cetirizine, desloratadine, diphenhydramine, fexofenadine, loratadine) were found to have high arrhythmogenic potential (medicines having so-called strong signals) and another six (cyclizine, dexchlorpheniramine, alimemazine, carbinoxamine, cyproeptadine and doxylamine) were found to be drugs with weak signals. It is interesting that most strong signals were associated with the second generation antihistamines for which previously no such adverese effects had been published 1 . Among them are loratadine and desloratadine which were, at that time, the most consumed antihistamines in Serbia. Due to this the aim of our analysis was to assess antihistamines consumption in Serbia for the following 5-year period (2011) (2012) (2013) (2014) (2015) , including also the consumption of drugs for common cold treatment containing an antihistamine as one of their active substances, as well as to check if any reports on adverse drug reactions to heart rhythm had been submitted to the National Pharmacovigilance Centre (NPC) for that period.
According (Table 1 ). The most preferred medicines for treatment of various forms of allergy in Serbia in the observed 5-year period, similarly to the previous one, were the second generation antihistamines, loratidine and desloratidine, followed by cetirizine and levocetirizine, as they are relatively free from anticholinergic, antiserotonergic and alpha adrenergic activity (1, 4, 5) . Consumption of antihistamines (ATC codes R01, and N02) in combination with other products for the treatment of common cold, represented approximately 12-21% of the consumption of antihistamines in the ATC R06 group, ranging from 1.44 DID in 2011 to 1.91 DID in 2015 (Table 2 ).
In view of the consumption of medicines for treatment of common colds in Serbia (Table 2) , and those containing antihistamines as active constituents, mainly pheniramine and chlorphenamine, we consider it necessary to monitor the utilisation of these medicines alongside any adverse effects on heart rhythm, considering that OTC medicines, such as antihistamines, are among the most advertised medicines in Serbia with sales expected to continue growing 6 . These findings should also be used to make recommendations to the Ministry of Health and the Health Insurance Fund of the Republic of Serbia if needed.
From 2011 to 2015, the NPC collected 25 reported cases of drug-induced arrhythmia. Among them was only one report of tachyarrhytmia associated by loratidine. This may be an under-estimated finding since the efficiency and success of any national program for monitoring the safety of medicines once on the market depend on the active participation of healthcare professionals in reporting any suspected adverse drug reactions. In Serbia these activities are insufficient. Spontaneous reporting should be viewed through the prism of professional and ethical responsibility, and healthcare professionals should direct future efforts towards intensifying the reporting of adverse drug reactions and integration of pharmacovigilance into their professional practice as part of their routine activities. Authorities should encourage this activities through physician`s societies in Serbia since spontaneous adverse reaction reporting by healthcare professionals, and also by patients and drug manufacturers, remains the main method for postmarketing surveillance in Serbia. Also, the authorities should actively conduct monitoring of any further cases of antihistamine-induced tachyarrhytmias to provide updated guidance to healthcare professionals in Serbia if and when the need arises. 
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